Basilea Pharmaceutica (BPMUF)
(Delayed Data from OTC)
$44.45 USD
0.00 (0.00%)
Updated Apr 10, 2024 01:56 PM ET
1-Strong Buy of 5 1
C Value D Growth C Momentum D VGM
Income Statements
Fiscal Year end for Basilea Pharmaceutica AG falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 176 | 155 | 162 | 136 | 135 |
Cost Of Goods | 30 | 26 | 26 | 26 | 19 |
Gross Profit | 146 | 129 | 136 | 110 | 116 |
Selling & Adminstrative & Depr. & Amort Expenses | 124 | 110 | 134 | 119 | 134 |
Income After Depreciation & Amortization | 21 | 19 | 1 | -9 | -17 |
Non-Operating Income | 3 | 4 | 0 | 1 | 1 |
Interest Expense | 12 | 10 | 9 | 8 | 6 |
Pretax Income | 12 | 13 | -7 | -16 | -23 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 12 | 13 | -7 | -16 | -22 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 12 | 13 | -7 | -16 | -22 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 23 | 21 | 2 | -8 | -16 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 1 | 1 | 2 |
Income After Depreciation & Amortization | 21 | 19 | 1 | -9 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 12.15 | 11.86 | 11.68 | 10.28 | 10.77 |
Diluted EPS Before Non-Recurring Items | 0.96 | 1.07 | -0.64 | -1.53 | -2.09 |
Diluted Net EPS (GAAP) | 0.96 | 1.07 | -0.64 | -1.53 | -2.09 |
Fiscal Year end for Basilea Pharmaceutica AG falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |